A000230 Stock Overview
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Ildong Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,720.00 |
| 52 Week High | ₩16,790.00 |
| 52 Week Low | ₩8,200.00 |
| Beta | 0.80 |
| 1 Month Change | -5.73% |
| 3 Month Change | -5.83% |
| 1 Year Change | -31.23% |
| 3 Year Change | -39.44% |
| 5 Year Change | -33.65% |
| Change since IPO | 361.23% |
Recent News & Updates
Recent updates
Is Ildong Holdings Co., Ltd. (KRX:000230) A Good Dividend Stock?
Apr 28
Can You Imagine How Ildong Holdings' (KRX:000230) Shareholders Feel About The 60% Share Price Increase?
Mar 04Ildong Holdings (KRX:000230) Has Debt But No Earnings; Should You Worry?
Feb 06
Tread With Caution Around Ildong Holdings Co., Ltd.'s (KRX:000230) 0.7% Dividend Yield
Jan 11How Much Of Ildong Holdings Co., Ltd. (KRX:000230) Do Insiders Own?
Dec 16How Much Have Ildong Holdings (KRX:000230) Shareholders Earned On Their Investment Over The Last Five Years?
Nov 20Shareholder Returns
| A000230 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.2% | 1.0% | 0.6% |
| 1Y | -31.2% | 10.4% | 6.9% |
Return vs Industry: A000230 underperformed the KR Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: A000230 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
| A000230 volatility | |
|---|---|
| A000230 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A000230 has not had significant price volatility in the past 3 months.
Volatility Over Time: A000230's weekly volatility has decreased from 8% to 3% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 84 | Dae-Chang Park | www.ildongholdings.co.kr |
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer’s disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics.
Ildong Holdings Co., Ltd. Fundamentals Summary
| A000230 fundamental statistics | |
|---|---|
| Market cap | ₩98.47b |
| Earnings (TTM) | -₩59.59b |
| Revenue (TTM) | ₩638.45b |
0.2x
P/S Ratio-1.7x
P/E RatioIs A000230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000230 income statement (TTM) | |
|---|---|
| Revenue | ₩638.45b |
| Cost of Revenue | ₩426.53b |
| Gross Profit | ₩211.92b |
| Other Expenses | ₩271.51b |
| Earnings | -₩59.59b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -5.28k |
| Gross Margin | 33.19% |
| Net Profit Margin | -9.33% |
| Debt/Equity Ratio | 159.7% |
How did A000230 perform over the long term?
See historical performance and comparison